Audited Standalone and Consolidated Financial Results for the year ended on March 31, 2025
Awaiting price reaction for this filing.
J.B. Chemicals & Pharmaceuticals reported healthy growth for FY25 on both standalone and consolidated basis. Consolidated revenue rose to ₹3,91,799 lakhs (up ~12.5% from ₹3,48,418 lakhs), while net profit grew ~19.4% to ₹65,958 lakhs (vs ₹55,263 lakhs). Standalone revenue increased ~12.9% to ₹3,72,292 lakhs with net profit of ₹65,254 lakhs (up ~20.1%). The board recommended a final dividend of ₹7 per share. The company also disclosed related party transactions for H2 FY25 as part of the integrated filing. Auditor Deloitte Haskins & Sells LLP issued an unmodified (clean) opinion on both standalone and consolidated results.
Solid double-digit revenue growth and ~20% standalone profit growth, combined with a declared dividend and clean audit, signal operational strength and shareholder returns. The strong operating cash flow (₹90,245 lakhs consolidated) and significant reduction in current borrowings improve the balance sheet, which is positive for shareholders.